Andrew J Yee

List of Publications by Year
in descending order

113 papers	2,666 citations	236612 25 h-index	205818 48 g-index
113 all docs	113 docs citations	113 times ranked	3688 citing authors

#	Article	IF	Citations
1	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
2	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e459-e469.	2.2	174
3	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 2022, 387, 132-147.	13.9	173
4	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncology, The, 2016, 17, 1569-1578.	5.1	164
5	Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761.	0.8	142
6	Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Science Translational Medicine, 2016, 8, 363ra147.	5.8	126
7	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplantâ€ineligible multiple myeloma. British Journal of Haematology, 2018, 182, 222-230.	1.2	118
8	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. JAMA Oncology, 2018, 4, e183267.	3.4	63
9	Myeloma and Bone Disease. Current Osteoporosis Reports, 2017, 15, 483-498.	1.5	55
10	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ¹⁸F-Florbetapir PET/CT. Journal of Nuclear Medicine, 2019, 60, 1234-1239.	2.8	54
11	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	3.3	54
12	Panobinostat and Multiple Myeloma in 2018. Oncologist, 2018, 23, 516-517.	1.9	51
13	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539.	3.3	50
14	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematology,the, 2022, 9, e143-e161.	2.2	44
15	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia, 2018, 32, 1838-1841.	3.3	42
16	Successful antiâ€CD19 CAR Tâ€cell therapy in HIVâ€infected patients with refractory highâ€grade Bâ€cell lymphoma. Cancer, 2019, 125, 3692-3698.	2.0	42
17	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839.	1.2	41
18	Improved Quantification of CardiacÂAmyloid Burden in SystemicÂLight ChainÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1325-1336.	2.3	41

#	Article	IF	Citations
19	Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 26-27.	0.6	40
20	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. British Journal of Haematology, 2014, 166, 401-409.	1.2	35
21	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. Clinical Cancer Research, 2014, 20, 3955-3961.	3.2	33
22	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	0.6	30
23	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clinical Interventions in Aging, 2012, 7, 331.	1.3	29
24	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 478-486.	3.2	29
25	Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Future Oncology, 2018, 14, 195-203.	1.1	27
26	How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 291-309.	1.8	27
27	Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics, 2014, 13, 2489-2500.	1.9	23
28	Successful Recovery After an Overdose of Argatroban. Annals of Pharmacotherapy, 2006, 40, 336-339.	0.9	22
29	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nature Cell Biology, 2021, 23, 1199-1211.	4.6	22
30	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 2016, 128, 491-491.	0.6	21
31	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
32	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 154-154.	0.6	19
33	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism inBRAF-Mutated Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6432-6444.	3.2	18
34	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiDÂ®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). Blood, 2015, 126, 3040-3040.	0.6	18
35	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. Blood, 2018, 132, 598-598.	0.6	17
36	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. Blood, 2019, 134, 3178-3178.	0.6	17

#	Article	IF	Citations
37	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2016, 128, 976-976.	0.6	17
38	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). Blood, 2016, 128, 3307-3307.	0.6	16
39	Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Advances, 2023, 7, 768-777.	2.5	15
40	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1998-2009.	3.3	14
41	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 2022, 6, 1232-1242.	2.5	14
42	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood, 2016, 127, 2355-2356.	0.6	13
43	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. Blood, 2019, 134, 3140-3140.	0.6	13
44	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 2022, 36, 1078-1087.	3.3	13
45	Clinical Grade â€œSNaPshotâ€•Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	2.7	12
46	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer, 2022, 128, 1996-2004.	2.0	12
47	The role of carfilzomib in relapsed/refractory multiple myeloma. Therapeutic Advances in Hematology, 2021, 12, 204062072110196.	1.1	11
48	Lifestyle considerations in multiple myeloma. Blood Cancer Journal, 2021, 11, 172.	2.8	11
49	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 3454-3454.	0.6	10
50	Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. Cancers, 2020, 12, 1223.	1.7	9
51	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood, 2015, 126, 4263-4263.	0.6	9
52	Minimal residual disease in multiple myeloma: why, when, where. Hematology American Society of Hematology Education Program, 2021, 2021, 37-45.	0.9	9
53	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial. Blood, 2013, 122, 3190-3190.	0.6	8
54	A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma. Blood, 2021, 138, 1675-1675.	0.6	8

#	Article	IF	Citations
55	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. Blood, 2014, 124, 4772-4772.	0.6	7
56	Sequencing of nontransplant treatments in multiple myeloma patients with active disease. Hematology American Society of Hematology Education Program, 2016, 2016, 495-503.	0.9	6
57	How We Approach Smoldering Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 1119-1125.	0.8	6
58	Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8015-8015.	0.8	6
59	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood, 2019, 134, 3169-3169.	0.6	6
60	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. Blood, 2019, 134, 1898-1898.	0.6	6
61	Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2015, 126, 4241-4241.	0.6	6
62	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 2022, 15, 594-603.	2.3	6
63	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). Blood, 2015, 126, 3055-3055.	0.6	5
64	Analysis of Hospitalization and Readmissions after CAR T Cell Therapy. Blood, 2018, 132, 2301-2301.	0.6	3
65	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	0.6	3
66	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. Blood, 2019, 134, 1872-1872.	0.6	3
67	Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease. Blood, 2012, 120, 328-328.	0.6	3
68	Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2014, 124, 4737-4737.	0.6	3
69	Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. Blood, 2021, 138, 3839-3839.	0.6	3
70	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2022, 97, 562-573.	2.0	3
71	Progressive Onset of Extracardiac and Myocardial Symptoms. Circulation, 2015, 132, 59-67.	1.6	2
72	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. Blood, 2011, 118, 3966-3966.	0.6	2

#	Article	IF	Citations
73	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2015, 126, 4246-4246.	0.6	2
74	Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2016, 128, 2124-2124.	0.6	2
75	A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2014, 124, 2142-2142.	0.6	2
76	Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs. Blood, 2015, 126, 3315-3315.	0.6	2
77	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. Blood, 2019, 134, 3066-3066.	0.6	2
78	Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma. Blood, 2021, 138, 5018-5018.	0.6	2
79	Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma. Blood, 2021, 138, 330-330.	0.6	2
80	448â€…Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. , 2021, 9, A476-A476.		2
81	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma. Blood, 2021, 138, 1649-1649.	0.6	2
82	Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. Cancer Research, 2022, 82, CT186-CT186.	0.4	2
83	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8012-8012.	0.8	2
84	Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort. JNCI Cancer Spectrum, 2021, 5, pkaa111.	1.4	1
85	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 2122-2122.	0.6	1
86	Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma. Blood, 2016, 128, 3320-3320.	0.6	1
87	Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease. Blood, 2012, 120, 3989-3989.	0.6	1
88	A Novel Brutonâ€²s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity. Blood, 2013, 122, 682-682.	0.6	1
89	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. Blood, 2018, 132, 1981-1981.	0.6	1
90	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and WaldenstrÃ¶m Macroglobulinemia. Blood, 2021, 138, 3801-3801.	0.6	1

#	Article	IF	Citations
91	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. Blood, 2021, 138, 3044-3044.	0.6	1
92	Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas. Blood, 2021, 138, 398-398.	0.6	1
93	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). Blood, 2021, 138, 4776-4776.	0.6	1
94	Minimal HLA Disparity and KIR Ligand Compatibility in Host Versus Graft Direction May Facilitate Donor Engraftment Following In Vivo and Ex Vivo T Cell Depleted (TCD) Nonmyeloablative Haploidentical Stem Cell Transplantation for Hematologic Malignancies.. Blood, 2005, 106, 3668-3668.	0.6	0
95	KIR Ligand Incompatibility in HLA-Identical Sibling Nonmyeloablative Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.. Blood, 2006, 108, 5371-5371.	0.6	0
96	Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.. Blood, 2007, 110, 5088-5088.	0.6	0
97	The Type of Upfront Induction Therapy for Newly Diagnosed Multiple Myeloma Patients Has No Significant Impact on Clinical Outcomes after Autologous Hematopoietic Stem Cell Transplantation.. Blood, 2007, 110, 5128-5128.	0.6	0
98	Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma. Blood, 2012, 120, 3990-3990.	0.6	0
99	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. Blood, 2012, 120, 3965-3965.	0.6	0
100	Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy. Blood, 2012, 120, 1871-1871.	0.6	0
101	Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma. Blood, 2012, 120, 4023-4023.	0.6	0
102	AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma. Blood, 2012, 120, 1822-1822.	0.6	0
103	Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution. Blood, 2016, 128, 800-800.	0.6	0
104	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. Blood, 2018, 132, 5600-5600.	0.6	0
105	Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma. Blood, 2019, 134, 4350-4350.	0.6	0
106	Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma. Blood, 2019, 134, 316-316.	0.6	0
107	Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma. Blood, 2019, 134, 2193-2193.	0.6	0
108	Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. Blood, 2019, 134, 3091-3091.	0.6	0

#	Article	IF	Citations
109	Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting. Blood, 2021, 138, 3803-3803.	0.6	0
110	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. Blood, 2021, 138, 4082-4082.	0.6	0
111	A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma. Blood, 2021, 138, 5043-5043.	0.6	0
112	Comparison of Denosumab Versus Intravenous (IV) Bisphosphonate Use for Hypercalcemia in Multiple Myeloma. Blood, 2020, 136, 14-16.	0.6	0
113	Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center. Blood, 2020, 136, 13-13.	0.6	0